老刘Diamond
Lv4
680 积分
2023-06-19 加入
-
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
18天前
已完结
-
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
-
Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens
1个月前
已完结
-
Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery
1个月前
已完结
-
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
1个月前
已完结
-
Optimism Surrounds Claudin 18.2 ADC
1个月前
已完结
-
A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
2个月前
已完结
-
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
2个月前
已关闭
-
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2个月前
已完结
-
Current developments in gastric cancer: from molecular profiling to treatment strategy
2个月前
已完结